Evidence map›Paper›PMID 33149763›Full record

ArticleTherapeutic advances in gastroenterology2020

Berberine for diarrhea in children and adults: a systematic review and meta-analysis.

Mingkun Yu, Xuejing Jin, Changhao Liang, Fanlong Bu, Deng Pan, Qian He, Yang Ming, Paul Little, Hongbo Du, Shibing Liang and 6 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Berberine, the major bioactive compound frombioRxiv : the preprint server for biology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. A Review ofMolecules (Basel, Switzerland) · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Mingkun YuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.ORCID https://orcid.org/0000-0002-5885-1612
Xuejing JinSchool of Public Health, University of Alberta, Edmonton, AB, Canada.
Changhao LiangCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Fanlong BuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Deng PanSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Qian HeSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Yang MingSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Paul LittlePrimary Care, Population Sciences and Medical Education Unit, University of Southampton, Southampton, UK.
Hongbo DuGastroenterology Department, DongZhiMen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Shibing LiangCollege of Basic Medical Sciences, Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi, China.
Ruixue HuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Chengze LiCollege of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, Yantai, Shandong Province, China.
Yanhong Jessika HuDepartment of Paediatrics, Murdoch Children's Research Institute, The Royal Children's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
Huijuan CaoCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Jianping LiuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Yutong FeiResearcher, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, School of Traditional Chinese Medicine, No. 11, North Third Ring Road, Chaoyang District, China.
Beijing University of Chinese Medicine · CNBinzhou Medical University · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNRoyal Children's Hospital · AUShanxi University of Traditional Chinese Medicine · CNUniversity of Alberta · CAUniversity of Southampton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiarrhea is a ubiquitous digestive system disease, leading to loss of fluid and electrolytes, and may be life-threatening, especially in children and adults who are immunosuppressed or malnourished. Berberine has a broad-spectrum antibiotic activity and is very widely used to treat diarrhea in China. No systematic review has been carried out to evaluate the evidence presented in clinical trials. The aim of this study was to assess the effectiveness and safety of berberine in diarrhea treatment among children and adults.

methodsSeven databases and two clinical trial registries were searched on 1 September 2019. Randomized controlled trials were included, where participants were diagnosed (first diagnosed) as having diarrhea according to clear diagnostic criteria. Berberine alone or in combination with Western medication as intervention were included. Subgroup analyses were conducted based on children or adults, acute or persistent diarrhea, infectious or noninfectious and treatment courses. Primary outcomes were clinical cure rate and duration of diarrhea. The GRADE tool was used to assess the quality of evidence.

resultsA total of 38 randomized controlled trials were included involving 3948 participants (including 27 trials on 2702 children) were included. Compared with antibiotics, berberine plus antibiotics showed better results in both adults and in children in general, especially when given for 7 days or 3 days in acute infectious diarrhea of children. Compared with the control groups, using berberine alone or in combination with montmorillonite, probiotics, and vitamin B increased the clinical cure rate of diarrhea. The use of berberine alone or berberine combined with montmorillonite reduced the duration of hospitalization. Using berberine had significantly better laboratory indicators (isoenzyme, inflammatory factors, myocardial enzyme, and fecal trait) and fewer systemic symptoms than the no berberine groups. Overall, 22 of 27 trials on children used berberine as an enema. No deaths and serious adverse events were reported. The quality of evidence of included trials was moderate to low or very low. The impact of different dosages, frequencies and treatment durations on the outcomes was not evaluated due to insufficient number of trials.

conclusionThis review demonstrated that berberine was generally effective in improving clinical cure rates and shortening the duration of diarrhea compared with control groups. No severe adverse event was reported. However, there is still a lack of high-quality evidence for evaluating the efficacy and safety of berberine.

trial registrationPROSPERO CRD42020151001 (available from http://www.crd.york.ac.uk/PROSPERO/).

Indexed as

antibioticberberinediarrheainflammatory factorsisoenzymemyocardial enzyme

Identifiers

PMID33149763
PMCPMC7586028
OpenAlexW3094596778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.